目的 分析平阳霉素碘油乳剂动脉内栓塞治疗(PLE-IASE)肝海绵状血管瘤(SCHL)的影响因素.方法 89例诊断明确的SCHL患者,瘤体直径为(8.3±3.8)cm.临床症状上仅有焦虑症状者53例,右上腹疼痛35例,Kagabach-Merrit综合征1例.PLE-IASE治疗前根据肝动脉造影表现进行动脉造影分型,分型确定后配制PLE经供血动脉注射.其中平阳霉素(PYM)用量为(9.8±4.4)mg,碘油(lipiodol,LP)用量为(5.9±2.9)ml.治疗结束后根据复查点片确定其碘油沉积状态.随访6～72个月,观察患者并发症发生情况,计算症状缓解率和瘤体缩小率.以瘤体缩小率为应变量,术前肿瘤直径、动脉造影分型、PYM用量、LP用量及碘油沉积状态为自变量,进行线性回归分析.结果 89例患者动脉造影分型富血型51例,乏血型26例,动静脉分流(AVS)型12例.治疗后碘油沉积状态良好64例,不良25例.随访结束时53例焦虑患者症状缓解,35例右上腹疼痛者33例缓解,2例术后仍有间歇性疼痛.1例Kagabach-Merrit综合征术后血小板恢复正常.随访症状缓解率98.7%.随访期间未发生严重并发症.线性回归分析显示动脉造影分型、PYM用量及碘油沉积状态对瘤体缩小率有显著影响,而术前肿瘤直径及LP用量对瘤体缩小率无显著影响.结论 PLE-IASE为一种安全有效的介入治疗方法,动脉造影分型、PYM用量及碘油沉积状态对瘤体缩小率有显著影响,而术前肿瘤直径及LP用量对瘤体缩小率无显著影响.%Objective To analyze the factors that might affect the therapeutic results of pingyangmycin-lipiodol emulsion intra-arterial sclerosing embolization (PLE-IASE) in treating symptomatic cavernous hemangioma of liver (SCHL). Methods PLE-IASE was performed in 89 patients with SCHL (32 males and 57 females). Before treatment the mean diameter of the hemangioma was (8.3±3.8) cm. Of 89 patients, 53 experienced anxiety, 35 suffered from right upper abdominal pain and the remaining one developed Kasabach-Merrit syndrome. Before PLE-IASE, the arteriographic classification was conducted based on hepatic arteriographic findings. Then pingyangmycin-lipiodol emulsion (PLE) was injected through the feeding artery. The dosage of pingyangmycin (PYM) was (9.8±4.4) mg and the dosage of lipiodol (LP) was (5.9±2.9) ml. The lipiodol deposition status was judged by the follow-up spot film taken immediately after PLE-IASE. The observations of the occurrence of complications, the relief of symptoms and the minification of SCHL were followed for 6-72 months after PLE-IASE. The linear regression analysis statistics was conducted by taking the minification as dependent variable and taking the arteriographic classification, lipiodol deposition status, the dosage of PYM, the dosage of lipiodol and the preoperative SCHL diameter as independent variable. Results Of all 89 cases of SCHL, hypervascular type was seen in 51, hypovascular type in 26 and arteriovenous shunt (AVS) type in 12. Good lipiodol deposition status was found in 64 patients and poor deposition in 25 patients after PLE-IASE. After PLE-IASE, the symptom of anxiety in 53 patients was relieved and the right upper abdominal pain was reduced in 33 cases although intermittent pain still remained in 2 patients. The blood platelet count of the patient with Kasabach-Merrit syndrome returned to normal after the treatment. The symptomatic relieve rate was 98.7%. No serious complications occurred in the follow-up period. The linear regression analysis showed that arteriographic classification, lipiodol deposition status and PYM dosage used in treatment had statistically significant impact on tumor minification, while the preoperative diameter of SCHL and lipiodol dosage used in treatment had no statistically significant impact on it. Conclusion PLE-IASE is an effective and safe interventional treatment for SCHL. Arteriographic classification, lipiodol deposition status and PYM dosage used in treatment have a significant correlation with the minification of SCHL, while the preoperative diameter of SCHL and lipiodol dosage used in treatment bear no relationship to the minification of SCHL.
展开▼
